Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10576MR)

This product GTTS-WQ10576MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10576MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8487MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ1425MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ12266MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ9906MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ13278MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ4159MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ6560MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ10798MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.